PF 06954522
Alternative Names: PF-06954522Latest Information Update: 25 Oct 2024
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 01 Sep 2024 Pfizer completes a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06393517)
- 30 Apr 2024 Pfizer initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06393517)
- 30 Apr 2024 Pfizer plans phase-I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) in April 2024 (Ref), (NCT06393517)